Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Weiding Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7188-1066; OpenAlex author ID A5058383798. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 5 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 17

  1. Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. Last author DOI 10.1007/s00535-026-02468-4↗
  2. Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma. Last author DOI 10.1016/j.ygeno.2025.111048↗
  3. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  4. The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. Last author DOI 10.1016/j.csbj.2024.09.032↗
  5. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1038/s41419-024-06589-7↗
  6. Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway. Co-author DOI 10.3724/abbs.2023286↗
  7. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Last author DOI 10.1002/ijc.34468↗
  8. Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2023.216411↗
  9. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. Last author DOI 10.1038/s41419-023-06313-x↗
  10. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/febs.16879↗
  11. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. Co-author DOI 10.3724/abbs.2023045↗
  12. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.01.026↗
  13. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  14. Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer. Last author DOI 10.3389/fimmu.2022.956984↗
  15. TGF-β1-induced RAP2 regulates invasion in pancreatic cancer. Last author DOI 10.3724/abbs.2022015↗
  16. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02147-z↗
  17. Cross-talk among AFAP1-AS1, ACVR1 and microRNA-384 regulates the stemness of pancreatic cancer cells and tumorigenicity in nude mice. Co-author DOI 10.1186/s13046-019-1051-0↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaizhou Jin · 16 shared papers, 2021–2026 · strength 3.09
  2. Xianjun Yu · 15 shared papers, 2021–2026 · strength 2.85
  3. Long‐Yun Ye · 13 shared papers, 2022–2026 · strength 2.62
  4. Qinglin Fei · 9 shared papers, 2022–2026 · strength 1.72
  5. Saimeng Shi · 7 shared papers, 2022–2024 · strength 1.28
  6. Tianjiao Li · 6 shared papers, 2022–2024 · strength 1.00
  7. Huiru Zhang · 5 shared papers, 2022–2024 · strength 0.91
  8. Duancheng Guo · 4 shared papers, 2023–2024 · strength 0.90
  9. Zhenyu Liao · 5 shared papers, 2022–2023 · strength 0.75
  10. Chen Liu · 4 shared papers, 2021–2025 · strength 0.71
  11. Xuan Lin · 3 shared papers, 2022–2023 · strength 0.43
  12. Zhiwen Xiao · 3 shared papers, 2022 · strength 0.42
  13. Guopei Luo · 2 shared papers, 2021–2025 · strength 0.31
  14. He Cheng · 2 shared papers, 2021–2022 · strength 0.28
  15. Huaxiang Xu · 2 shared papers, 2022 · strength 0.26
  16. Liang Liu · 2 shared papers, 2022 · strength 0.26
  17. Xianjun Yu · 1 shared paper, 2025 · strength 0.24
  18. Bing Peng · 1 shared paper, 2025 · strength 0.19
  19. Xu Wang · 1 shared paper, 2025 · strength 0.19
  20. Jin Xu · 1 shared paper, 2025 · strength 0.19
  21. He Cheng · 1 shared paper, 2025 · strength 0.19
  22. Wenyan Xu · 1 shared paper, 2025 · strength 0.19
  23. Wei Wang · 1 shared paper, 2025 · strength 0.19
  24. Chenghao Shao · 1 shared paper, 2025 · strength 0.19
  25. Rong Liu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.